EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER…

By B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, Steve Hurley, J. Kleiman, M. Gatlin. 2003

999 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the preventionof sudden cardiac death (2015, unknown): “Catheter ablation in conjunction with anti-arrhythmic drugs is an effective palliative therapy for terminating VT storm and eliminating one or more inducible VTs in the majority of patients, but recurrences are common and these patients require ICD backup.624,625 11.6 Valvular heart disease Manageme”
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2017, methodology): “The Eplerenone Post-AMI Heart failure Efficacy and SUrvival Study (EPHESUS) randomized 6642 post-MI patients with LV dysfunction (LVEF <_40%) and symptoms of heart failure/diabetes to eplerenone or placebo within 3–14 days after their infarction.(397) After a mean follow-up of 16 months, there was a”
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) (2019, background): “In patients with severe LV systolic dysfunction, the addition of an MR antagonist to standard drug therapy with an RA system inhibitor + a β-blocker + a diuretic further improves the prognosis [779, 966].”